Risk factors and prognosis assessment for acute kidney injury: The 2020 consensus of the Taiwan AKI Task Force

• Published in: Journal of the Formosan Medical Association Vol. 120; no. 7; pp. 1424 - 1433
• Main Authors: Chen, Jia-Jin, Kuo, George, Hung, Chi-Chih, Lin, Yu-Feng, Chen, Yung-Chang, Wu, Ming-Ju, Fang, Ji-Tseng, Ku, Shih-Chi, Hwang, Shang-Jyh, Huang, Yen-Ta, Wu, Vin-Cent, Chang, Chih-Hsiang
• Format: Journal Article
• Language: English
• Published: Singapore Elsevier B.V 01.07.2021; Elsevier
• Subjects: Acute kidney injury; Furosemide stress test; Risk stratification; APACHE-II; SOFA; RRT; Acute kidney injury; FST; Risk stratification; Furosemide stress test; CKD; AKI
• ISSN: 0929-6646; 1876-0821
• DOI: 10.1016/j.jfma.2021.02.013

Risk and prognostic factors for acute kidney injury (AKI) have been published in various studies across various populations. We aimed to explore recent advancements in and provide updated recommendations on AKI risk stratification and information about local AKI risk factors. The Taiwan Acute Kidney Injury Task Force reviewed relevant recently published literature and reached a consensus after group meetings. Systemic review and group discussion were performed. We conducted a meta-analysis according to the PRISMA statement for evaluating the diagnostic performance of the furosemide stress test. Several risk and susceptibility factors were identified through literature review. Contrast-associated AKI prediction models after coronary angiography were one of the most discussed prediction models we found. The basic approach and evaluation of patients with AKI was also discussed. Our meta-analysis found that the furosemide stress test can be used as a prognostic tool for AKI progression and to identify patients with AKI who are at low risk of renal replacement therapy. Factors associated with de novo chronic kidney injury or renal non-recovery after AKI were identified and summarized. Our review provided practical information about early identification of patients at high risk of AKI or disease progression for Taiwan local clinics.